Abstract
AbstractThis is the primary report of the randomized, placebo-controlled phase 3 BRIGHT AML 1019 clinical trial of glasdegib in combination with intensive chemotherapy (cytarabine and daunorubicin) or non-intensive chemotherapy (azacitidine) in patients with untreated acute myeloid leukemia. Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% confidence interval [CI]: 0.782–1.408; two-sided p = 0.749) and non-intensive (n = 325; HR 0.99; 95% CI: 0.768–1.289; two-sided p = 0.969) studies. The proportion of patients who experienced treatment-emergent adverse events was similar for glasdegib versus placebo (intensive: 99.0% vs. 98.5%; non-intensive: 99.4% vs. 98.8%). The most common treatment-emergent adverse events were nausea, febrile neutropenia, and anemia in the intensive study and anemia, constipation, and nausea in the non-intensive study. The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Clinical trial registration: ClinicalTrials.gov: NCT03416179.
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference29 articles.
1. NIH National Cancer Institute. Surveillance, Epidemiology and End Results Program (SEER). Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML). (Last Update 2022). https://seer.cancer.gov/statfacts/html/amyl.html.
2. Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127:2049–61. https://doi.org/10.1002/cncr.33458.
3. de Leeuw DC, Ossenkoppele GJ, Janssen J. Older patients with acute myeloid leukemia deserve individualized treatment. Curr Oncol Rep. 2022. https://doi.org/10.1007/s11912-022-01299-9.
4. Potenza L, Borelli E, Bigi S, Giusti D, Longo G, Odejide O, et al. Early palliative care in acute myeloid leukemia. Cancers. 2022; 14. https://doi.org/10.3390/cancers14030478.
5. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18:809–16. https://doi.org/10.1038/sj.leu.2403289.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献